Multiple Myeloma Therapeutics Market Segmentation:
Treatment Type (Chemotherapy, Targeted Therapy, Immunomodulating Agents, Stem Cell Transplantation, Radiation Therapy)
Targeted therapy segment is projected to account for multiple myeloma therapeutics market share of more than 33.6% by the end of 2035. The disease-specific pathways of these drugs are designed to increase the rate of survival for cancer patients. This further implies in broadened usage of targeted therapies in various treatment processes. The improved outcomes for multiple myeloma are inspiring manufacturers to invest in R&D to expand available options. In June 2024, Mission Bio launched a multi-omics solution, Tapestri to provide precise insights for R&D in multiple myeloma therapeutics. This product suite will help to classify cell types in the process of identifying immunotherapeutic targets including BCMA.
Route of Administration (Oral, Parenteral)
Based on the route of administration, the oral segment is estimated to capture a significant share of the multiple myeloma therapeutics market. The growth is propelled by patient adherence and convenient usage of oral supplements. These therapies are being increased in efficacy by combining them with other treatments. For instance, in October 2024, Jhonson & Jhonson received extensive approval for DARZALEX SC formulation for 1st stage myeloma patients. The quadruplet therapy can be used with a combination of bortezomib, lenalidomide, and dexamethasone. The new oral therapy is examined by the PERSEUS study, ensuring a 58% reduction in disease progression or mortality. Such innovative ways of taking supplements are creating the scope to develop more personalized regiments.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
Route of Administration |
|
|
Disease Type |
|
|
End use |
|
